查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1618302

2024 - 2032 年外分泌胰臟功能不全治療市場機會、成長動力、產業趨勢分析與預測

Exocrine Pancreatic Insufficiency Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 101 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球外分泌胰臟功能不全治療市場達27億美元，預計2024年至2032年複合年成長率為5.6%。透過以下方法進行管理：醫療和飲食方法的結合。 EPI 的治療策略旨在減輕症狀、促進營養吸收並改善患者的生活品質。 EPI 診斷技術的重大進步正在改善檢測並支持更及時、有效的治療。最新的研究旨在檢測明確的生物標記物，這些標記正在改變胰臟功能評估並促進早期診斷。

糞便彈性蛋白酶-1 已成為一種重要的生物標記物，其低水平表明胰腺功能不全，從而提高了診斷精度並有助於市場擴張。市場按治療類型分為營養管理和胰酶替代療法 (PERT)，其中 PERT 細分市場收入領先，到 2023 年將達到 23 億美元。腹脹和脂肪瀉。透過促進脂肪、蛋白質和碳水化合物的適當吸收，PERT 可以預防與 EPI 相關的併發症，包括營養不良、維生素缺乏和意外體重減輕，從而顯著改善患者的生活品質。就藥物類型而言，市場包括專為 PERT 設計的關鍵藥物，每種藥物都提供獨特的配方，以增強營養吸收並緩解與 EPI 相關的症狀。

利用脂肪酶、蛋白酶和澱粉酶等酶，這些療法針對效率進行了最佳化，利用腸溶膠囊確保酶在消化發生的小腸中有效釋放。這些製劑有多種劑量可供選擇，可根據患者的個別需求量身訂做治療方案。 2023 年，北美佔據 EPI 治療市場的主要佔有率，預計到 2032 年成長將達到 24 億美元。此外，北美全面的保險覆蓋範圍和完善的醫療保健系統增強了患者獲得專業藥物和護理的機會，進一步支持市場擴張並改善患者的治療結果。市場正在不斷發展。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 27億美元
預測值 44億美元
複合年成長率 5.6%

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 慢性胰臟炎（CP）和囊性纖維化的盛行率不斷增加
      • 人口老化加劇
      • 診斷方面的進步
      • 製藥業的技術進步
    • 產業陷阱與挑戰
      • 治療費用高
      • 認知和教育有限
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按處理方式，2021 - 2032 年

  • 主要趨勢
  • 營養管理
  • 胰酵素替代療法（PERT）

第 6 章：市場估計與預測：按藥物類型，2021 - 2032 年

  • 主要趨勢
  • 克瑞翁
  • 曾佩普
  • 胰髒
  • 維奧卡塞
  • 其他藥物種類

第 7 章：市場估計與預測：按症狀分類，2021 年 - 2032 年

  • 主要趨勢
  • 腹痛
  • 便秘
  • 腹瀉
  • 脂肪糞便
  • 減肥
  • 其他症狀

第 8 章：市場估計與預測：按配銷通路，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：公司簡介

  • Abbott Laboratories
  • AbbVie
  • Digestive Care
  • Essential Pharma
  • Nestle
  • Nordmark Pharma
  • Sun Pharmaceutical Industries
  • Viatris
  • Vivus
  • Zentiva Pharma UK
簡介目錄
Product Code: 9379

The Global Exocrine Pancreatic Insufficiency Treatment Market reached USD 2.7 billion in 2023, with a projected growth rate of 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency, characterized by a lack of pancreatic enzymes critical for nutrient digestion and absorption, is managed through a combination of medical and dietary approaches. Treatment strategies for EPI aim to reduce symptoms, boost nutrient absorption, and improve the quality of life for those affected by the condition. Significant advancements in diagnostic techniques for EPI are improving detection and supporting more timely, effective treatments. Latest research has aimed at detecting definite biomarkers, which are transforming pancreatic function assessments and facilitating earlier diagnosis.

Fecal elastase-1 has emerged as an essential biomarker, with low levels indicating pancreatic insufficiency, enhancing diagnostic precision and contributing to market expansion. The market is segmented by treatment type into nutritional management and pancreatic enzyme replacement therapy (PERT), with the PERT segment leading in market revenue, reaching USD 2.3 billion in 2023. PERT aids in restoring the body's ability to digest essential nutrients, alleviating common symptoms such as bloating and steatorrhea. By enabling proper absorption of fats, proteins, and carbohydrates, PERT prevents complications associated with EPI, including malnutrition, vitamin deficiencies, and unintended weight loss, significantly improving patients' quality of life. In terms of drug types, the market includes key medications designed for PERT, each offering unique formulations to enhance nutrient absorption and relieve symptoms associated with EPI.

With enzymes like lipase, protease, and amylase, these therapies are optimized for efficiency, utilizing enteric-coated capsules to ensure enzymes are effectively released in the small intestine where digestion occurs. These formulations are available in various dosages, allowing for treatment customization based on individual patient requirements. North America accounted for a major share of the EPI treatment market in 2023, with an anticipated growth reaching USD 2.4 billion by 2032. The region benefits from advanced healthcare infrastructure, extensive research initiatives, and broad access to PERT, driving growth in EPI treatment availability. Additionally, comprehensive insurance coverage and well-established healthcare systems in North America enhance patient access to specialized medications and care, further supporting market expansion and improved patient outcomes.As advancements in diagnostic methods and therapeutic options continue to evolve, the global EPI treatment market is expected to see steady growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$2.7 Billion
Forecast Value$4.4 Billion
CAGR5.6%

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
      • 3.2.1.2 Growing aging population
      • 3.2.1.3 Advancements in diagnosis
      • 3.2.1.4 Technological advancements in pharmaceutical industry
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Limited awareness and education
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Nutritional management
  • 5.3 Pancreatic enzyme replacement therapy (PERT)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Creon
  • 6.3 Zenpep
  • 6.4 Pancreaze
  • 6.5 Viokace
  • 6.6 Other drug types

Chapter 7 Market Estimates and Forecast, By Symptom, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Abdominal pain
  • 7.3 Constipation
  • 7.4 Diarrhea
  • 7.5 Fatty stools
  • 7.6 Weight loss
  • 7.7 Other symptoms

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 AbbVie
  • 10.3 Digestive Care
  • 10.4 Essential Pharma
  • 10.5 Nestle
  • 10.6 Nordmark Pharma
  • 10.7 Sun Pharmaceutical Industries
  • 10.8 Viatris
  • 10.9 Vivus
  • 10.10 Zentiva Pharma UK